Poly Medicure Limited (POLYMED) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,620 (+1.35% day change)
Key ratios
- P/E ratio
- 50.96
- P/B ratio
- 3.89
- ROE (%)
- 10.37
- ROCE (%)
- 9.78
- Debt/Equity
- 0.11
- Dividend yield (%)
- 0.29
- Market cap (₹ Cr)
- 16,420.48
Forensic checks
Piotroski F-Score: 3/9 · Altman Z-Score: 11.4 · Beneish M-Score: -1.14
InvestSights quality score
61.8/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Domestic business revenue growth: guided 25–30% YoY, delivered 18% YoY (FY24) — missed guidance
- Renal segment revenue growth: guided 50% YoY, delivered 60% YoY (FY25) — exceeded guidance
Latest earnings call (Q1 FY27)
AI summary: The most important signal is that PolyMed’s reported growth is increasingly being supported by higher-technology therapies and acquisitions, but the near-term quality of earnings will depend on whether organic exports accelerate and gross margins normalise without weakening EBITDA. Q1 delivered consolidated revenue of ₹525 crore, up 30.3%, but organic revenue grew 12.4%,…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.